FRESH TUMOR ASSAY FOR REDISCOVERY OF CLOSED-IND DRUGS

用于重新发现封闭新药的新鲜肿瘤检测

基本信息

批准号：
3493176
负责人：
LARRY M WEISENTHAL
金额：
$ 5万
依托单位：
WEISENTHAL CANCER GROUP
依托单位国家：
美国
项目类别：
财政年份：
1993
资助国家：
美国
起止时间：
1993-05-07 至 1993-11-07
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/3493176
关键词：
antineoplastics bioassay blood /lymphatic neoplasm cryopreservation cytotoxicity drug screening /evaluation human tissue lymphocyte neoplasm /cancer pharmacology stainings tissue /cell culture

项目摘要

Cancer drug development suffers greatly from a lack of preclinical models to reveal human disease-specific activity of new agents. We will determine whether skilled and insightful application of a fresh human tumor assay based on the concept of total tumor cell kill can identify clinical situations in which "abandoned" drugs have important clinical antineoplastic activity. We will take 40 drugs with INDs issued between 1960 and 1980 and 10 reference agents and test these drugs against fresh human normal and neoplastic tissues using the DiSC assay. The study will attempt to identify potential clinical indications for 40 closed-IND drugs. Drugs will be tested in normal human cell types, hematologic neoplasms, and solid tumors, to get pilot data as to normal cell versus hematologic versus solid tumor specificity and to prepare for more extensive testing in Phase 2 of the study. In Phase 2, the 50 drugs will receive testing against a broad variety of human neoplasms in order to identify potential niche indications for one or more of. these agents which would be worthy of clinical Phase II trials and to indicate whether total cell kill is a more robust in vitro endpoint than is cell proliferation.

癌症药物的开发很大，缺乏临床前模型揭示新药物的人类疾病特异性活性。我们将确定熟练和有见地的新鲜人的应用基于总肿瘤细胞杀死的概念可以识别肿瘤分析 “废弃”药物具有重要临床的临床情况抗肿瘤活性。我们将服用40种药物，并在 1960年和1980年和10个参考代理，并针对新鲜进行测试人类正常组织和肿瘤组织使用圆盘测定法。研究将试图确定40个闭合的潜在临床指示毒品。药物将在正常的人类细胞类型中进行测试，血液学肿瘤和实体瘤，以获取针对正常细胞的试验数据血液学与实体瘤的特异性，并准备更多在研究的第2阶段进行了广泛的测试。在第2阶段，这50种药物将接受针对各种各样的人类肿瘤的测试确定一个或多个的潜在小众适应症。这些代理这值得临床II期试验，并指出是否总细胞杀死比细胞更强大增殖。